<?xml version="1.0" encoding="UTF-8"?>
<p>For similar reasons, many companies are also repurposing vaccines. In the two recent outbreaks of coronavirus infection, severe acute respiratory syndrome (SARS) which caused an epidemic in the early 2000s and Middle East respiratory syndrome (MERS) which caused multiple outbreaks between 2015 and 2018, work which had started on vaccines was subsequently stopped when the epidemics were successfully contained. Inovio Pharmaceuticals had already initiated work on a DNA vaccine for MERS prior to the COVID-19 outbreak, allowing the company to develop a potential vaccine for COVID-19 rapidly.
 <sup>
  <xref rid="bibr7-1470320320926902" ref-type="bibr">7</xref>
 </sup> Sanofi is repurposing a SARS protein vaccine,
 <sup>
  <xref rid="bibr8-1470320320926902" ref-type="bibr">8</xref>
 </sup> and Novavax are working on several repurposed vaccines that will reportedly be ready for human trials in spring 2020.
 <sup>
  <xref rid="bibr9-1470320320926902" ref-type="bibr">9</xref>,
  <xref rid="bibr10-1470320320926902" ref-type="bibr">10</xref>
 </sup>
</p>
